Drug intelligence / Profile preview

LEO 153339

Development stage: Phase 1
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Oral

Overview

LEO 153339 is an investigational oral small molecule drug being developed by LEO Pharma, a Danish pharmaceutical company. It acts as an inhibitor of interleukin-17 (IL-17), a pro-inflammatory cytokine implicated in the pathogenesis of several autoimmune diseases, including psoriasis. The compound is currently in early clinical development, with phase I trials evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers. As of now, no human efficacy data have been published. The primary indication under investigation appears to be psoriasis[4][8].

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on LEO 153339.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEO 153339.

Explore the full profile